Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process-Reference-Cited by-同舟云学术

Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process

Published:2011-08-25 Issue:12 Volume:41 Page:1076-1087
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Choo Edna F,Alicke Bruno,Boggs Jason,Dinkel Vikki,Gould Stephen,Grina Jonas,West Kristina,Menghrajani Kapil,Ran Yingqing,Rudolph Joachim,Wenglowsky Steve

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/00498254.2011.603384

Reference35 articles.

1. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

2. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

3. Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

4. Mutations of the BRAF gene in human cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo-in vitro correlation of antitumor activity of heat shock protein 90 (HSP90) inhibitors with a pharmacokinetics/pharmacodynamics analysis using NCI-N87 xenograft mice;Xenobiotica;2021-08-19

2. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor;European Journal of Pharmaceutical Sciences;2019-08

3. Why Decreasing Lipophilicity Alone Is Often Not a Reliable Strategy for Extending IV Half-life;ACS Medicinal Chemistry Letters;2018-04-19

4. Recent progress in the identification of BRAF inhibitors as anti-cancer agents;European Journal of Medicinal Chemistry;2014-01

5. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor;International Journal of Pharmaceutics;2013-09